Age-Related Macular Degeneration Market

Age-Related Macular Degeneration Market Research: Current Status, Trends, and Opportunities

Age-related macular degeneration (AMD) is a common eye disease that affects people aged 50 years and above, causing damage to the macula, a part of the retina that is responsible for central vision. AMD is one of the leading causes of blindness worldwide and its prevalence is expected to increase due to the aging population. In this market research article, we will provide an overview of the current market size and market share of the AMD industry, the key players in the industry, major trends and drivers affecting the industry, and opportunities and threats in the industry. We will also discuss regulatory and legal issues affecting the industry and target demographics of the industry.

Current Market Size and Market Share

The global AMD market is expected to grow at a CAGR of + 7 %  by 2028, reaching a market size of ~ USD 11 billion by 2028.

The North American region dominated the market with a revenue share of 44.6% in 2020, followed by Europe and Asia-Pacific. The high prevalence of AMD and the availability of advanced treatment options are the major factors driving the growth of the market.

Key Players-

• ALLERGAN
• Bausch & Lomb Incorporated
• Bayer AG
• Hoffmann La Roche
• GlaxoSmithKline PLC
• Novartis AG
• Ophthotech Corporation
• Pfizer Inc
• Regeneron Pharmaceuticals
• Rxi Pharmaceuticals Inc.
• Santen Pharmaceuticals Co.
• Valeant Pharmaceuticals International

Segmentation-

By Product        

• Wet AMD
• Dry AMD

By Drugs

• Lucentis
• Eylea
• Avastin
• Others

By Route of Administration

• Intravenous
• Intravitreal

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Regional & Country Level:

• North America

  • US.
  • Canada

• Europe

  • UK.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of the Middle East and Africa

Major Trends and Drivers

The increasing prevalence of AMD, growing geriatric population, and rising healthcare expenditure are the major trends driving the growth of the AMD market. The development of new and advanced therapies such as anti-VEGF drugs and gene therapy is expected to fuel the growth of the market. In addition, the increasing adoption of combination therapies and the launch of new drugs with better efficacy and safety profiles are expected to drive the market growth.

Opportunities and Threats

The increasing focus of the pharmaceutical industry on developing innovative therapies for the treatment of AMD presents several opportunities for the growth of the market. However, the high cost of therapy and the lack of awareness among patients regarding the disease and available treatment options pose a threat to the market growth. In addition, the availability of biosimilars and the entry of new players in the market could lead to price erosion and intensify competition in the market.

Regulatory and Legal Issues

The regulatory landscape for the AMD market is complex, with several regulatory agencies such as the US FDA, EMA, and PMDA regulating the approval and marketing of drugs for the treatment of AMD. The increasing scrutiny of regulatory agencies regarding the safety and efficacy of drugs could delay the approval and launch of new drugs in the market. In addition, patent expirations and legal disputes over intellectual property could affect the market growth.

Target Demographics and Preferences

AMD is a disease that primarily affects the elderly population aged 50 years and above. The increasing awareness among patients and healthcare professionals regarding the importance of early diagnosis and treatment of AMD is driving the demand for effective and safe therapies. In addition, the preference for convenient and easy-to-use therapies is also driving the growth of the market.

Pricing Trends

The pricing of therapies for AMD varies across different segments of the market, with anti-VEGF drugs being the most expensive. The high cost of therapy is a major concern for patients and healthcare providers, which is driving the demand for cost-effective and alternative therapies. The entry of biosim

ilars and the increasing competition in the market could lead to price erosion and lower the cost of therapy, making it more accessible to a larger population.

Conclusion

The AMD market is expected to grow at a steady pace in the coming years, driven by the increasing prevalence of the disease, the development of new and advanced therapies, and the growing geriatric population. However, the high cost of therapy, regulatory and legal issues, and the lack of awareness among patients regarding the disease and treatment options pose challenges to the market growth. The key players in the industry are focusing on developing innovative therapies to address these challenges and expand their market share. The future of the AMD market looks promising, with the potential for new breakthroughs in therapy development and increasing access to cost-effective treatment options.